When a Defense IME Recommends Discontinuing Medications

James Wong — Founder & CEO, LienScripts | March 29, 2026 | 8 min read

Defense independent medical examinations frequently recommend discontinuing or reducing medications in personal injury cases. This article provides the attorney response strategy to protect pharmacy lien balances and ongoing treatment when facing adverse IME opinions.

When a Defense IME Recommends Discontinuing Medications

A defense independent medical examination (IME) that recommends discontinuing plaintiff medications is one of the most consequential events in a personal injury case with a pharmacy lien. The IME opinion, if unchallenged, gives the defense a medical basis to argue that all post-IME pharmacy lien charges are unnecessary. Attorneys must respond strategically to protect both the client's ongoing treatment and the pharmacy lien balance.

Defense IME physicians frequently recommend medication discontinuation or reduction as a standard element of their opinion
An unchallenged IME discontinuation opinion can be used to cap the pharmacy lien at the IME date, eliminating recovery for all subsequent medications
LienScripts provides MERIT (Medication Evaluation & Rationale for Injury Treatment) documentation that directly rebuts IME medication opinions with pharmacist-level clinical analysis
The treating physician's response to the IME opinion is the most critical document in preserving the pharmacy lien

[!KEY] Never allow a defense IME medication discontinuation recommendation to go unanswered — the treating physician must produce a written response explaining why the medications remain clinically necessary, or the defense will use the unanswered IME opinion as the medical basis for reducing the pharmacy lien.

How Defense IMEs Target Medications

Defense IME physicians follow a predictable approach when evaluating medication regimens in PI cases. Understanding the methodology reveals the weaknesses in the opinion.

The Typical IME Medication Opinion

The defense physician examines the plaintiff for 15-30 minutes, reviews selected medical records, and produces a report containing one or more of these medication conclusions:

"The patient no longer requires [medication] as the acute phase of injury has resolved" — This ignores chronic pain syndromes, central sensitization, and ongoing structural pathology
"The patient should be weaned off narcotic/opioid medications" — This recommendation is made without a weaning protocol and without considering the consequences of abrupt discontinuation
"Generic alternatives should be substituted for all brand-name medications" — Applied as a blanket recommendation without medication-specific clinical analysis
"The medication regimen is excessive for the documented injuries" — The overutilization opinion applied to ongoing prescriptions

The Strategic Goal

The defense is building a record to argue at mediation or trial that all pharmacy lien charges after the IME date are unreasonable. If the IME physician recommended discontinuation on a specific date, the defense will argue that a "reasonable" pharmacy lien balance ends on that date.

The Attorney Response Framework

Step 1: Obtain the Full IME Report Immediately

Do not rely on a summary. The full IME report reveals what records the examiner reviewed (and which they did not), how long the examination lasted, what objective tests were performed, and the specific basis for each medication recommendation.

[!TIP] Request the IME physician's notes, not just the final report. The handwritten examination notes often reveal that the physical examination was cursory — documenting limited range of motion testing, no neurological examination, or a 12-minute total encounter for a multi-system injury plaintiff.

Step 2: Have the Treating Physician Respond in Writing

This is the most critical step. The treating physician must produce a written response — whether a letter, addendum to the medical record, or formal rebuttal report — that:

Identifies each medication the IME recommended discontinuing
Explains the ongoing clinical indication for each medication based on current examination findings and symptom reports
Addresses why the IME recommendation is clinically inappropriate for this specific patient
Documents any objective findings (imaging, nerve conduction studies, clinical examination) that support continued medication need

According to James Wong, PharmD, founder of LienScripts, "The treating physician who has managed this patient for months or years has clinical information that a 20-minute IME cannot capture. The written response converts that longitudinal clinical knowledge into an exhibit-ready document."

Step 3: Request LienScripts MERIT Documentation

The LienScripts MERIT report provides independent pharmacist-level analysis of medication necessity that supplements the treating physician's response. The MERIT addresses:

Clinical rationale for each medication's continued use, tied to documented diagnoses
Pharmacological consequences of abrupt discontinuation (withdrawal risk, rebound symptoms, pain crisis)
Standard-of-care references supporting the current medication regimen
Specific responses to the IME physician's medication recommendations

LienScripts generates a MERIT (Medication Evaluation & Rationale for Injury Treatment) report for every case, providing pharmacist-signed documentation for demand packages.

Step 4: Challenge the IME Physician's Qualifications

Not all IME physicians are qualified to opine on medication management:

Orthopedic surgeons opining on pain management medication protocols may be practicing outside their clinical expertise
Neurologists recommending discontinuation of psychiatric medications (PTSD, anxiety) may lack relevant training
Any physician recommending opioid discontinuation without a weaning protocol is providing a clinically dangerous recommendation

As Amar Lunagaria, PharmD, LienScripts' Chief Pharmacist explains, "When an orthopedic IME physician recommends discontinuing gabapentin for neuropathic pain, we ask a simple question: when was the last time that physician managed a gabapentin taper in their own clinical practice? The answer reveals whether they are qualified to make that recommendation."

[!KEY] An IME physician who recommends medication discontinuation without providing a specific tapering protocol is making an academically theoretical recommendation, not a clinically actionable one — and that distinction matters at trial.

Specific Medication Discontinuation Scenarios

Opioid Discontinuation Recommendations

The most common and most dangerous IME recommendation. Abrupt opioid discontinuation causes withdrawal syndrome, pain crisis, and potential medical emergency. The treating physician's response should emphasize:

The medical dangers of abrupt cessation without a supervised taper
The current dose and duration, which determine withdrawal risk
Whether any taper attempts have been made and why they were unsuccessful
The lack of a specific tapering protocol in the IME report

Muscle Relaxant Discontinuation

IME physicians frequently claim that muscle relaxants are only appropriate for the "acute phase" (first 2-4 weeks). The rebuttal addresses ongoing documented muscle spasm, the difference between acute spasm and chronic myofascial pain, and the patient's functional status with and without the medication.

Anti-Anxiety and Antidepressant Discontinuation

IME recommendations to discontinue psychiatric medications prescribed for accident-related PTSD or anxiety are particularly problematic. These medications require supervised tapering over weeks to months. An IME recommendation to "discontinue" without a psychiatric transition plan is clinically irresponsible.

Neuropathic Pain Medication Discontinuation

Gabapentin, pregabalin, and duloxetine for documented nerve injury or radiculopathy cannot be simply stopped. The IME must explain what alternative pain management the patient should receive, or the recommendation is incomplete.

Preserving the Pharmacy Lien After an Adverse IME

The key principle: the pharmacy lien balance does not automatically become unreasonable because a defense IME disagrees with the treatment plan. The IME opinion is one medical opinion — the treating physician's opinion, supported by longitudinal clinical knowledge, is another. The factfinder resolves the dispute.

To protect the lien:

Document the treating physician's disagreement with the IME in writing
Obtain MERIT documentation addressing the specific IME recommendations
Continue necessary medications under the treating physician's direction
Prepare the treating physician to testify about why the IME recommendations were clinically inappropriate

Contact LienScripts to request MERIT documentation addressing adverse IME medication opinions in your cases.

Related Resources

Frequently Asked Questions

Can a defense IME recommendation cap the pharmacy lien at the IME date?

Not automatically. The IME opinion is one medical opinion that must be weighed against the treating physician's ongoing clinical judgment. However, an unanswered IME recommendation creates a strong argument for the defense to cap lien recovery at the IME date, which is why a written treating physician response is critical.

What should the treating physician include in their IME response?

The response should address each medication the IME recommended discontinuing, explain the ongoing clinical indication based on current findings, identify why the IME recommendation is inappropriate for this patient, and document objective evidence supporting continued treatment.

Is an IME physician qualified to recommend medication discontinuation?

It depends on the physician's specialty and the medications in question. An orthopedic surgeon opining on psychiatric medication management or a neurologist recommending opioid tapering without a specific protocol may be practicing outside their expertise, which is a valid challenge to the opinion's weight.

How does MERIT help counter adverse IME opinions?

MERIT provides independent pharmacist-level clinical analysis that addresses each IME medication recommendation with standard-of-care references, pharmacological consequences of discontinuation, and specific clinical rationale for continuing each medication tied to documented diagnoses.